FDA Peptide Update: Category 2 Removals Explained Content Analysis of US FDA Warning Letters Issued to Compounding Pharmacies Regarding Violations of Current Good Manufacturing Practices Between 2017 and 2022 Journal of Pharmaceutical Innovation Springer Nature Link BPC 157 Banned: Key Facts on the Latest FDA Decision Valor Compounding Pharmacy Inc. Berkeley, CA. Untitled Letter issued 03 23 2023 The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York